Nektar Therapeutics (NKTR) Shares are Up 2.28%

Nektar Therapeutics (NKTR) : Traders are bullish on Nektar Therapeutics (NKTR) as it has outperformed the S&P 500 by a wide margin of 12.83% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.74%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.28% in the last 1 week, and is up 10.55% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 4.32% and the 50-Day Moving Average is 11.68%.The 200 Day SMA reached 27.77% Nektar Therapeutics is up 28.48% in the last 3-month period. Year-to-Date the stock performance stands at 13.23%.


Nektar Therapeutics (NKTR) : 6 investment research analysts covering Nektar Therapeutics (NKTR) have an average price target of $19.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $25 and the lowest target is $14 for the short term. Analysts expect the variance to be within $3.56 of the average price.

For this week, the average consensus of the company shares are rated as a Strong Buy. Nektar Therapeutics (NASDAQ:NKTR): stock was range-bound between the intraday low of $18.93 and the intraday high of $19.28 after having opened at $19.25 on Fridays session. The stock finally closed in the red at $19.25, a loss of -0.88%. The stock remained in the red for the whole trading day. The total traded volume was 1,370,326 shares. The stock failed to cross $19.28 in Fridays trading. The stocks closing price on Thursday was $19.08.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.